Gilead Sciences

Gilead Sciences

Biopharmaceutical company developing innovative medicines

About Gilead Sciences

Simplify's Rating
Why Gilead Sciences is rated
B+
Rated B on Competitive Edge
Rated A on Growth Potential
Rated B on Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Overview

Company Historically Provides H1B Sponsorship

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and manufacturing practices. The company's goal is to enhance health equity and access to care, working with communities globally to ensure that its medicines reach those in need.

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's $32 billion U.S. investment will create over 3,000 jobs by 2028.
  • The reformulation of lenacapavir offers long-acting HIV prevention, improving patient adherence.
  • Gilead's top five ranking in the Most JUST list highlights its corporate responsibility.

What critics are saying

  • A $202 million settlement for legal violations may damage Gilead's reputation.
  • Layoffs of 150 employees, including senior management, could disrupt company operations.
  • AI-driven drug discovery companies pose a competitive threat to Gilead's traditional R&D.

What makes Gilead Sciences unique

  • Gilead focuses on innovative medicines for unmet needs like HIV/AIDS and liver diseases.
  • The company invests heavily in R&D to maintain a robust pipeline of new treatments.
  • Gilead's partnerships enhance product offerings and expand market reach globally.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$4410M

Above

Industry Average

Funded Over

3 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Fierce Pharma
May 8th, 2025
Gilead tees up $11B in new US manufacturing, R&D investments

This time it's Gilead coming to the table with a fresh $11 billion in hand to spend across its manufacturing and research centers in the U.S.

Gilead Sciences
May 7th, 2025
Gilead U.S. Investment to Create $43 Billion in Value to U.S. Economy

Gilead to invest $32 billion in U.S. manufacturing and R&D through 2030 and create more than 3,000 direct and indirect jobs by 2028

Constantine Cannon
May 5th, 2025
Gilead Pays $202M to Settle False Claims Act Kickback Charges

On April 29, the Department of Justice (DOJ) announced that California-based pharmaceutical giant Gilead Sciences agreed to pay $202 million to settle charges of violating the False Claims Act and Anti-Kickback Statute.

Financial Modeling Prep
May 2nd, 2025
Amgen Inc. (NASDAQ:AMGN) Surpasses Earnings and Sales Estimates in Q1 2025

Amgen competes with other biotech giants like Gilead Sciences and Biogen.

SFist
Apr 2nd, 2025
April Fool's Day Around the Bay: Bob Lee's Family Has Sued His Convicted Killer Nima Momeni

Foster City-based HIV drug company Gilead Sciences is laying off nearly 150 people, and the job cuts are significant among senior members of the company's management.

Recently Posted Jobs

Sign up to get curated job recommendations

Director – Clinical Development Oncology - MD

$261.4k - $338.3k/yr

San Mateo, CA, USA

Director – Medical Insights - Inflammation - Viral Hepatitis & COVID - Gmso

$226.2k - $292.7k/yr

San Mateo, CA, USA + 1 more

Director – Employee Relations Partner

$210.4k - $272.3k/yr

San Mateo, CA, USA

See All Jobs

Gilead Sciences is Hiring for 239 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Gilead Sciences's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to Gilead Sciences

AbbVie

AbbVie

North Chicago, Illinois

Amgen

Amgen

Thousand Oaks, California

Vertex Pharmaceuticals

Vertex Pharmaceuticals

Boston, Massachusetts

Director – Medical Insights - Inflammation - Viral Hepatitis & COVID - Gmso

$226.2k - $292.7k/yr

San Mateo, CA, USA + 1 more

Director – Employee Relations Partner

$210.4k - $272.3k/yr

San Mateo, CA, USA

See All Jobs

Gilead Sciences is Hiring for 239 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Gilead Sciences's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to Gilead Sciences

AbbVie

AbbVie

North Chicago, Illinois

Amgen

Amgen

Thousand Oaks, California

Vertex Pharmaceuticals

Vertex Pharmaceuticals

Boston, Massachusetts